Company: SXTPW
Filing Date: 2025-07-07
Form Type: S-1
Source: 0001213900-25-061842
Chunk: 60

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-07
Form: S-1
Chunk 60
---

of common stock issuable from time to time upon exercise of the Pre-Funded Warrants and Warrants offered hereby.

Common Stock

The description of our
common stock under “Common Stock” in this section is incorporated herein by reference.

Warrants

The following summary
of certain terms and provisions of the Warrants accompanying the shares of common stock and the Pre-Funded Warrants that are
being issued hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the Warrants, the form of which
is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review
the terms and provisions of the form of Warrant for a complete description of the terms and conditions of the Warrants. The Series A-1
Warrant and Series A-2 Warrant are identical except with regard to their duration.

Duration and Exercise Price

Each Warrant offered
hereby will have an assumed exercise price of $2.455 per share, the last reported sale price of our common stock on The Nasdaq Capital
Market on July 2, 2025, and will be exercisable beginning on the effective date of the Warrant Stockholder Approval, provided, however,
if the Pricing Conditions are met, the Warrants will be exercisable upon issuance (the “Initial Exercise Date”). The exercise
price and number of shares of common stock issuable upon exercise of the warrants is subject to appropriate adjustment in the event of
stock dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price. The Warrants will
be issued separately from the common stock and Pre-Funded Warrants and may be transferred separately immediately thereafter. The Warrants
will be issued in certificated form only. The Series A-1 Warrants will expire on the fifth anniversary of the Initial Exercise Date.
The Series A-2 Warrants will expire on the 18-month anniversary of the Initial Exercise Date.

We intend to promptly,
and in no event later than 90 days after the consummation of this offering, seek stockholder approval for the issuance of shares of common
stock issuable upon exercise of the Warrants but we cannot assure you that such stockholder approval will be obtained, provided, however,
that, if and only if the Pricing Conditions are satisfied, then we will not seek Warrant Stockholder Approval. We have agreed with the
investors in this offering that, if we do not obtain stock